Aviceda Therapeutics appoints Patrick Johnson to its board of directors


Aviceda Therapeutics appoints Patrick Johnson, a strategic pharmaceutical executive, to its board of directors.

©SFIO CRACHO / stock.adobe.com

Aviceda Therapeutics appoints Patrick Johnson, a strategic pharmaceutical executive, to its board of directors as it continues to develop treatments for geographic atrophy. (Image Credit: Adobe Stock/SFIO CRACHO)

Aviceda Therapeutics announced the appointment of Patrick Johnson to its board of directors. Patrick is an accomplished business leader and entrepreneur with a proven track record of enabling pharmaceutical and biotechnology companies to maximize the value of their brands and realize the potential of their innovations.

“We are thrilled to welcome Patrick to Aviceda’s board of directors as we advance our pipeline through key milestones in 2023 and beyond,” said Mohamed A. Genead, MD, CEO & President, Co-Founder of Aviceda Therapeutics in the press release. “Patrick will bring significant industry expertise, and his strategic counsel will be invaluable to Aviceda as we continue to advance our technology platform in late-stage clinical development for patients with GA due to age-related macular degeneration and broader therapeutic applications.”

Patrick is a strategic pharmaceutical executive with two decades of broad cross-functional expertise in all aspects of corporate operations, including in-depth experience with global M&A, business development, strategic transactions, fundraising, clinical operations, scientific research, and corporate finance. Previously, he gained exceptional sell-side and buy-side transactional experience as head of business development for eye care and drug delivery at Allergan. Patrick’s deal experience ranges from some of the largest transactions in the pharmaceutical industry to small partnerships, having raised multiple rounds of venture financing for numerous start-up companies. He is currently leading operations on a global Phase 3 clinical studies as President of Sydnexis Inc. Co-author of global patent portfolio and author/co-author of numerous peer-reviewed journal articles, Patrick also has specific subject matter expertise with a PhD in retinal development and post-doctoral research in retinal degeneration (focusing on macular degeneration).

“It is a privilege to join Aviceda’s board as the organization advances towards delivering new treatment options for people living with retinal diseases, many of whom have been significantly underserved for decades,” said Dr. Johnson. “I look forward to working alongside this dynamic team and advancing a diverse pipeline through development and into commercialization.”

Related Videos
Video 4 - "Treating Geographic Atrophy in Patients with Concurrent Neovascular AMD"
Video 3 - "Managing a Patient with Bilateral Geographic Atrophy"
Video 2 - "FDA-approved Therapies for Geographic Atrophy"
Video 1 - "Geographic Atrophy: Overview, Diagnosis, and Progression"
Marion Munk, MD, PhD, presenting slides
Marion Munk, MD, PhD, presenting slides
Retinal Inner Layer Disorganization and OCT in Uveitic Macular Edema: Insights from Dr. Amitha Domalpally
ARVO 2024: Study Reveals Faricimab's Potential for Extended Dosing in nAMD
© 2024 MJH Life Sciences

All rights reserved.